Pyxis Group, a diversified advisory firm serving the global industrial and commodities sectors, today announced the ...

Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...

On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...

Maroussi, Greece – April 24, 2026 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), an international shipping company, announced today that its Chief Financial Officer, Henry Williams, will be stepping ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based ...